

Balaxi Pharmaceuticals Limited

Date: 25.07.2025

To,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Newspaper Advertisement – Disclosure under Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement published today i.e., July 25, 2025 regarding the following:

- a) Information on 82nd Annual General Meeting (“AGM”) of the Company scheduled to be held on Monday, August 25, 2025 at 11.00 AM (IST) through Video Conferencing/ Other Audio – Visual Means;
- b) Manner of despatch of AGM Notice along with Annual Report 2024-25; &
- c) Manner of registration of email address and casting of vote through remote e-voting/ e-voting during the AGM.

The aforesaid information is also being hosted on the Company’s website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

Mohith Kumar Khandelwal
(Company Secretary and Compliance Officer)
Membership No.: F11243

Encl: A/a

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

This announcement is not an offer of securities for sale in the United States or elsewhere. This announcement has been prepared for publication in India only and is not for publication or distribution, directly or indirectly, in or into the United States. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable U.S. state securities laws. There will be no public offering in the United States and the securities being offered in this announcement are not being offered or sold in the United States.

Balaxi Pharmaceuticals Limited

Registered Office: Plot No.409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598 | **Phone:** +91 40 23555300 | **Email:** secretarial@balaxi.in | **Website:** www.balaxipharma.in

INFORMATION REGARDING 82nd ANNUAL GENERAL MEETING TO BE HELD THROUGH VIDEO CONFERENCING ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM")

Notice is hereby given that the 82nd Annual General Meeting ("AGM") of the Members of Balaxi Pharmaceuticals Limited ("the Company") is scheduled to be held on **Monday, August 25 2025 at 11.00 a.m. (IST)** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") in compliance with the applicable provisions of the Companies Act, 2013 ("the Act") and the rules made thereunder read with General Circular No. 9/2024 dated September 19,2024, issued by the Ministry of Corporate Affairs (MCA) and circular issued by Securities and Exchange Board of India (SEBI) vide circular no. SEBI/HO/CFD/CFDPOD-2-P/CIC/2024/133 dated October 03,2024 ("SEBI Circular") and other applicable circulars and notifications issued (including any statutory modifications or re-enactments thereof for the time being in force and as amended from time to time), Companies are permitted to hold General Meetings through VCOAVM, without the physical presence of the members at a common venue.

In Compliance with the abovementioned circulars, Notice of the AGM along with the Annual Report 2024-25 will be sent only through electronic mode to those Members whose e-mail address is registered with the Company/ Registrar and Transfer Agent / Depository Participants / Depositories. Members may note that the Notice and Annual Report 2024-25 will also be available on the Company's website <https://balaxipharma.in/>, website of the Stock Exchange i.e., National Stock Exchange of India Limited <https://www.nseindia.com/>, and on the website of National Securities Depository Limited <https://www.evotingsndl.com/>. The Company shall send physical copy of the Annual Report 2024-25 to the members who specifically request for the same by sending an email at secretarial@balaxi.in.

In compliance with Section 108 of the Act, read with the corresponding rules, Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of SEBI circulars, the Company is providing remote e-voting facility to its members, to enable them to cast their votes electronically through the facility provided by National Securities Depository Limited (NSDL). Additionally, the facility for voting during the AGM will also be made available. Members present in the AGM through VC/OAVM and who have not casted their vote on the resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through the e-voting system during the AGM. Detailed instructions for remote e-voting, e-voting during the AGM and attending the AGM through VC/ OAVM will be provided in the Notice of the AGM.

Members who have not registered their e-mail address are requested to register the same in respect of shares held in electronic form with the Depository through their Depository Participant(s) and in respect of shares held in physical form by writing to the Company's RTA, Aarthi Consultants Private Limited, 1-2-285, Domalguda, Hyderabad – 500 029, E-mail: info@aarthicconsultants.com.

Members holding shares in physical mode are requested to note that SEBI vide its circulars SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/655 dated November 3, 2021, SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/687 dated December 14, 2021 and SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 and SEBI/HO/MIRSD/POD-1/P/CIR/2023/181 dated November 17,2023 has simplified the process for investor service requests. SEBI has made it mandatory for holders of physical securities to furnish PAN, bank account details, contact details, specimen signature and nomination for their corresponding folio numbers. SEBI has notified forms for the purpose, as detailed below:

Forms	Description
Form ISR-1	Request for registering PAN, bank account details, signature, mobile, email-id, address or changes / up-dation thereof
Form ISR- 2	Confirmation of Signature of securities holder by the Banker
Form SH-13	Nomination form
Form ISR-3	Declaration for Nomination opt-out
Form SH- 14	Change in Nomination

The above forms can be downloaded from the Company's website at <https://balaxipharma.in/investor-contacts>. Accordingly, members are requested to make service requests / update their records by submitting a duly filled and signed forms, along with the related proofs listed in the forms to Company's RTA, Aarthi Consultants Private Limited, 1-2-285, Domalguda, Hyderabad – 500 029, E-mail: info@aarthicconsultants.com.

For Balaxi Pharmaceuticals Limited

Sd/-
Mohit Kumar Khandelwal
(Company Secretary & Compliance Officer)
Membership No.: F11243

Date: July 24,2025
Place: Hyderabad

...continued from previous page.

Modification/ revision/cancellation of Bids	
Upward revision of Bids by QIBs and Non-Institutional Bidders categories ²	Only between 10.00 a.m. and up to 4.00 p.m. IST on Bid/ Offer Closing Date
Upward or downward Revision of Bids or cancellation of Bids by RILs	Only between 10.00 a.m. on the Bid/Offer Opening Date and up to 5.00 p.m. IST

²UPI mandate end time and date shall be at 5.00 pm on the Bid/Offer Closing Date.

* QIBs and Non-institutional Bidders can neither revise their bids downwards nor cancel/withdraw their Bids


ASBA*

Simple, Safe, Smart way of Application!!!

*Applications supported by blocked amount (ASBA) is a better way of applying to offers by simply blocking the fund in the bank account. For further details, check the section on ASBA below.

Mandatory in Public offers.

No cheque will be accepted.



UPI-Now available in ASBA for all individual investors applying in public Offers where the application amount is up to ₹ 5,00,000, applying through Registered Brokers, Syndicate, CDPs & RTAs. UPI-Now mandatory in ASBA for Retail Individual Bidders ("RIBs") applying through Registered Brokers, DP's & RTA. RIBs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021 and CBDT circular no.7 of 2022 read with press release dated March 30, 2022, read with press release dated March 28, 2023 and any subsequent press release in this regard.

*ASBA has to be availed by all the investors except Anchor investors. UPI may be availed by (i) Retail Individual Bidders; (ii) Non-Institutional Investors with an application size of up to ₹500,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA Form & abridged prospectus and also please refer to the section "Offer Procedure" beginning on page 470 of the RHP. The process is also available on the website of Association of Investment Bankers ("AIBI") and Stock Exchange in the General information Document. ASBA Forms can be downloaded from the Stock Exchanges and can be obtained from the list of banks that is displaying on website of SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>. List of banks supporting UPI is also available on the website of SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35>. For the list of UPI Apps and Banks live on IPO, please refer to the link: www.sebi.gov.in. Axis Bank Limited and HDFC Bank Limited has been appointed as Sponsor Bank for the Offer in accordance with the requirements of the SEBI Circular dated November 1, 2018, as amended. UPI Bidders Bidding using UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. For Offer related queries, please contact the BRLM on its email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll-free number: 18001201740 and mail id: ipo_upi@npci.org.in

LIABILITY OF MEMBERS OF THE COMPANY: Limited by shares.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: As on the date of the RHP the authorized share capital of the Company is ₹ 400 million, divided into 80,000,000 Equity Shares of face value ₹ 5 each. The issued, subscribed, and paid-up share capital of the Company before the Offer is ₹ 288,946,020 divided into 57,789,204 Equity Shares of face value ₹ 5 each. For details of the Capital Structure, see chapter titled "Capital Structure" beginning on page 90 of the RHP.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed by them at the time of signing of the Memorandum of Association of our Company: Vinod Kumar Jain (10,000 Equity Shares); Arun Kumar Jain (35,000 Equity Share); Anoop Agrawal (35,000 Equity Shares), Alok Agarwal (5000 Equity Shares), Neetu Agrawal (5000 Equity Shares), Rachna Agrawal (5000 Equity Shares) and Jyoti Jain (5000 Equity Shares) equity shares of face value ₹ 10 each.

LISTING: The Equity Shares Offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges in terms of the Chapter IX of the SEBI (ICDR) Regulations, as amended from time to time. Our Company has received an in-principle listing approval letter dated December 02, 2024, from the Stock Exchanges. For the purpose of this Offer, the Designated Stock Exchange will be the BSE Limited.

DISCLAIMER CAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"): It is to be distinctly understood that submission of the Offer document to SEBI should not, in any way, be deemed or construed that the same has been cleared or approved by SEBI. SEBI does not take any responsibility either for the financial soundness of any scheme or the project for which the offer is proposed to be made or for the correctness of the statements made or opinions expressed in the offer document, the BRLM, Pantomath Capital Advisors Private Limited, has certified that the disclosures made in the offer document are generally adequate and are in conformity with the SEBI ICDR regulations, for disclosure and investor protection in force for the time being. This requirement is to facilitate investors to take an informed decision for making an investment in the proposed Offer .

DISCLAIMER CAUSE OF BSE (the Designated Stock Exchange): As required, a copy of the Draft Red Herring Prospectus has been submitted to BSE. The disclaimer clause as intimated by BSE is set forth as follows :
"BSE Limited ("the Exchange") has given vide its letter dated December 2, 2024, permission to this Company to use the Exchange's name in this offer document as one of the stock exchanges on which this company's securities are proposed to be listed. The Exchange has scrutinized this offer document for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner:-
a. warrant, certify or endorse the correctness or completeness of any of the contents of this offer document; or
b. warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or
c. take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company.
and it should not for any reason be deemed or construed that this offer document has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever."

DISCLAIMER CAUSE OF NSE: As required, a copy of this Offer Document has been submitted to National Stock Exchange of India Limited (hereinafter referred to as NSE). NSE has given vide its letter Ref.: NSE/LIST/4628 dated December 2, 2024, permission to the Issuer to use the Exchange's name in this Offer Document as one of the Stock Exchanges on which this Issuer's securities are proposed to be listed. The Exchange has scrutinized this draft offer document for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Issuer. It is to be distinctly understood that the aforesaid permission given by NSE should not in any way be deemed or construed that the offer document has been cleared or approved by NSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of this offer document; nor does it warrant that this Issuer's securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer.

In case of any revision to the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLM, for reasons to be recorded in writing, extend the Bid / Offer Period for a minimum of One Working Day, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the website of the BRLM and at the terminals of the Syndicate Member(s) and by intimation to the Designated Intermediaries and the Sponsor Bank, as applicable.



This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR"), read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in terms of Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 30% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs" and such portion, the "QIB Portion"). Our Company may in consultation with the BRLM, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds only, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Price"), in accordance with SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 30% of the Offer shall be available for allocation to Non-Institutional Bidders out of which (a) one third of such portion shall be reserved for applicants with application size of more than ₹ 0.2% Million and upto ₹ 1 Million; and (b) two third of such portion shall be reserved for applicants with application size of more than ₹ 1.00 Million, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of non-institutional investors and not less than 40% of Offer shall be available for allocation to Retail Individual Bidders ("RIBs") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders, (expect Anchor Investors), are mandatorily required to participate in the Offer through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Accounts (as defined hereinafter) including UPI ID in case of RIBs in which the Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For further details, please see the chapter titled "Offer Procedure" beginning on page 470 of the RHP.

Bidders / Applicants should ensure that DP ID, PAN and Client ID and UPI ID (for RIBs bidding through the UPI mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidder/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to an Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020, and press release dated June 25, 2021, read with press release dated September 17, 2021 and CBDT circular No. 7 of 2022 dated March 30, 2022

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF OUR COMPANY AS REGARDS ITS OBJECTS : For information on the main objects and other objects of our Company, see "History and Certain Corporate Matters" on page 218 of the RHP. The Memorandum of Association of our Company is a material document for inspection in relation to the Offer. For further details, see the section "Material Contracts and Documents for Inspection" on page 522 of the RHP.

Every person who desires to apply for or otherwise acquire any securities of this Issuer may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription /acquisition whether by reason of anything stated or omitted to be stated herein or any other reason whatsoever."

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer including the risks involved. The Equity Shares Offered in the Offer have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section titled "Risk Factors" beginning on Page 31 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <div>Pantomath Capital Advisors Private Limited Pantomath Nucleus House, Saki-Vihar Road, Andheri-East, Mumbai – 400072 Maharashtra, India. Tel: 1800 889 8711; Email: highway ipo@pantomathgroup.com; Website: www.pantomathgroup.com Investor Grievance Id: investors@pantomathgroup.com; Contact Person: Amit Maheshwari SEBI Registration No: INM000012110</div>	 <div>Bigshare Services Private Limited Office No. S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai – 400 093, Maharashtra, India; Telephone: +91 226 263 8200; Email: ipo@bigshareonline.com Investor grievance email: investor@bigshareonline.com; Contact Person: Vinayak Morbale Website: www.bigshareonline.com; SEBI Registration number: INR000001385</div>	<div>Palak Rathore, 57-FA, Scheme No. 94, Pipliyahana Junction, Ring Road, Indore- 452016, Madhya Pradesh, India. Telephone: +91- 731 4047177; E-mail: cs@highwayinfrastructure.in</div> <div>Investors may contact the Company Secretary and Compliance Officer, or the Registrar to the Offer in case of any pre-Offer or post-Offer related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode etc. For all Offer related queries and for redressal of complaints, Investor may also write to the BRLM.</div>

AVAILABILITY OF RHP: Investors should note that investment in Equity Shares involves a high degree of risk and investors are advised to refer to the Red Herring Prospectus and the Risk Factor contained therein, before applying in the Offer. Full copy of the Red Herring Prospectus shall be available at the website of SEBI at www.sebi.gov.in, websites of Stock Exchanges i.e BSE Limited and NSE Limited at www.bseindia.com and www.nseindia.com respectively, website of the Company at www.highwayinfrastructure.in, the website of Book Running Lead Manager www.pantomathgroup.com.

AVAILABILITY OF ABRIDGED PROSPECTUS: A copy of abridged prospectus shall be available on the website of the Company, the BRLM and Registrar to the Offer www.highwayinfrastructure.in, www.pantomathgroup.com, www.bigshareonline.com

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company, Book Running Lead Manager and Syndicate Member, Registered Brokers, RTA and CDPs participating in the Offer. Bid-cum-application Forms will also be available on the websites of, BSE (www.bseindia.com) , NSE (www.nseindia.com) and the designated branches of SCSBs, the list of which is available at websites of the Stock Exchange and SEBI.

Syndicate Member: Asit C. Mehta Investment Intermediates Limited

Sub-Syndicate Member: Prabhudas Lilladher Pvt Limited, Viren M. Shah, KJMC Capital Market Services Limited, AXIS Capital Limited, RR Equity Brokers Pvt. Limited, Almondz Global Securities Limited, Dalal & Broacha Stock Broking Pvt. Limited, LKP Securities Limited, Jobanputra Fiscal Services Pvt. Limited, Nuvama Wealth And Investment Limited Edelweiss Broking Limited), Motilal Oswal Financial Services Limited, Pravin Ratilal Share And Stock Brokers Limited, Innovate Securities Pvt. Limited, Iifi Securities Limited, Sharekhan Limited, Centrum Broking Limited, Alankit Imaginations Limited, JM Financial Services Limited, SMC Global Securities Limited, Anand Rathl Share And Stock Brokers Limited, HDFC Securities Limited, YES Securities (India) Limited, Finwizard Technology Pvt. Limited, ICICI Securities Limited, IDBI Capital Markets & Securities Limited, Reliance Securities Limited Nirmal Bang Securities Pvt Limited, Keynote Capitals Limited, Systematix Shares And Stocks (India) Limited, Db(International) Stock Brokers Limited, Inventure Growth & Securities Limited, Kantilal Chhaganlal Securities Pvt.Limited, Kotak Securities Limited, Shicap Securities Limited, Religare Broking Limited, Monarch Network Capital Limited, Tradebulls Securities (P) Limited, O J Financial Services Limited.

Escrow Collection Bank: Axis Bank Limited **Refund Bank:** Axis Bank Limited **Public Offer Bank:** HDFC Bank Limited **Sponsor Banks:** HDFC Bank Limited & Axis Bank Limited

UPI: UPI Bidders can also bid through UPI Mechanism.

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

Place: Indore, Madhya Pradesh
Date: July 24, 2025.

HIGHWAY INFRASTRUCTURE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the RHP with Registrar of Companies on July 24, 2025. The RHP shall be available on the website of the BRLM to the Offer at www.pantomathgroup.com and website of BSE (www.bseindia.com) and NSE (www.nseindia.com). Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 31 of the RHP. Potential investors should not rely on the RHP for making any investment decision.

This announcement is not an offer of securities for sale in the United States or elsewhere. This announcement has been prepared for publication in India only and is not for publication or distribution, directly or indirectly, in or into the United States. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable U.S. state securities laws. There will be no public offering in the United States and the securities being offered in this announcement are not being offered or sold in the United States.

For Highway Infrastructure Limited

On behalf of the Board of Directors

Sd/-
Palak Rathore
Company Secretary and Compliance Officer

INDIAN ENERGY EXCHANGE LIMITED

CIN: L74999DL2007PLC277039
Regd. Office: 1st Floor Unit No. 1.14(a), Avanta Business Centre, Southern Park, D-2, District Centre, Saket, New Delhi-110017, India
Tel.: +91-11-3044 6511, **Tel.:** +91-120-4648 100, **Fax No.:** +91-120-4648 115
Website: www.ixindia.com, **E-mail:** compliance@ixindia.com

PUBLIC NOTICE TO SHAREHOLDERS OF THE INDIAN ENERGY EXCHANGE LIMITED FOR TRANSFER OF SHARES TO THE INVESTOR EDUCATION AND PROTECTION FUND (IEPF) ACCOUNT

(As per Section 124(6) of the Companies Act, 2013)

Shareholders are hereby informed that pursuant to the provisions of Section 124(6) of the Companies Act, 2013, read with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules"), as amended, the Final Dividend declared for the Financial Year 2017-18, which remained unclaimed for a consecutive period of seven (7) years will be credited to the IEPF on October 23, 2025. The corresponding shares on which dividends were unclaimed for seven (7) consecutive years shall also be transferred as per the procedure set out in the Rules.

In compliance with the above said provisions, the list of shareholders who have not encashed their dividend for seven (7) consecutive years and whose shares are due for such transfer to the IEPF's Account is available on the Company's website at <https://www.ixindia.com/investors/unclaimed-dividend>. Individual communications have been sent to all the concerned shareholders, who have not encashed the final dividend for the financial year 2017-18 and all the subsequent dividends declared and paid by the Company, and whose unclaimed dividend and corresponding shares are liable to be transferred to IEPF as per the aforesaid Rules, at their latest available addresses, advising them to forward requisite documents to the Company or its Registrar and Share Transfer Agent (RTA), KFin Technologies Limited, to claim the unpaid dividends and shares.

In the event valid claims are not received on or before October 08, 2025 from the concerned shareholders, the Company shall proceed to transfer the unclaimed dividend and corresponding Equity shares in favour of IEPF authority without any further notice. Please note that no claim shall lie against the Company in respect of unclaimed dividend amount and shares transferred to IEPF pursuant to the said rules. However, please note that after such transfer, concerned shareholders/claimants can claim the transferred shares along with dividends from the IEPF Authority, for which details are available at www.iepf.gov.in.

In case the shareholders have any queries on the aforesaid matters and need any assistance, they may contact the Company and RTA as under:

Indian Energy Exchange Limited Compliance Department Plot No. C-001/A/1, 9 th Floor, Max Towers, Sector 16B, Noida, Gautam Buddha Nagar, Uttar Pradesh-201301 Phone No.: 0120-4648100 E-mail: compliance@ixindia.com	KFin Technologies Limited Unit: Indian Energy Exchange Limited Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad-500 032 Toll Free No.: 1800-3094001 E-mail: enward.ris@kfintech.com
--	---

For Indian Energy Exchange Limited
Sd/-
Vineet Harialka
CFO, Company Secretary & Compliance Officer
Membership No.: ACS 16264

AJMERERA REALTY & INFRA INDIA LIMITED

CIN No. L27104MH1985PLC035659
Regd. Office: 2nd Floor, "Cit Mail", New Link Road, Andheri (West), Mumbai- 400053
Tel: +91-22-6698 4000 **Fax:** +91-22-2632 5902
Email: investors@ajmera.com **Website:** www.ajmera.com

NOTICE

Transfer of Dividend and Equity Shares to Investor Education & Protection Fund

This Notice is published pursuant to Section 124(6) of the Companies Act, 2013 ("Act") read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("the Rules") contains provisions for transfer of unclaimed dividend and transfer of shares, in respect of which dividend remains unclaimed for seven consecutive years or more to the IEPF Account. Companies are required to inform the shareholders at the latest available addresses whose shares are liable to be transferred to the IEPF Authority, three months prior to the due date of transfer of shares and simultaneously publish the notice in the newspapers.

Individual communication will be sent to the registered address of the shareholders whose dividends have been lying unclaimed for seven consecutive years and whose shares are liable to be transferred to IEPF, simultaneously.

The complete details of such shareholders are uploaded on the website viz. <https://ajmera.com/>

In case the dividends are not claimed by the concerned Shareholders on or before October 27, 2025, for Final Dividend of the Financial year 2017-18, necessary steps will be initiated by the Company to transfer shares held by the concerned shareholders to the IEPF without further notice in the following manner:

In this connection, please note the following:

- In case shares are in a physical form: New share certificate(s) will be issued and transferred in favour of the IEPF on completion of necessary formalities. The original share certificate(s) which stand registered in the name of shareholders will be deemed cancelled and non-negotiable.
- In case shares are in electronic form: The Company shall inform the depository by way of corporate action for transfer of shares lying in shareholders demat account in favour of the IEPF.

The Shareholders may note that in the event of transfer of shares and unclaimed dividends to the IEPF, concerned shareholders are entitled to claim the same from the IEPF Authority by sending physical copy of requisite documents to the Company or Registrar and Share Transfer Agent of the Company for obtaining the entitlement letter, pursuant to Circular dated July 20, 2022 issued by the IEPF Authority, and thereafter submitting online application in the prescribed Form IEPF-5 available on the website viz. www.mca.gov.in and access the Form under MCA services>Company e-filing>IEPF Services.

The Shareholders may further note that the details of the unclaimed dividends and shares of the concerned shareholders uploaded by the Company on its website viz. <https://ajmera.com/> shall be treated as adequate notice in respect of issue of the new share certificate(s) by the Company for the purpose of transfer of shares to the IEPF pursuant to the Rules. Please note that no claim shall lie against the Company in respect of the unclaimed dividend and equity shares transferred to the IEPF.

For any queries/clarifications on the above matter, shareholders are requested to contact the Company's Registrar and Transfer Agent, MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) Unit: Ajmera Realty & Infra India Limited, C-101, 247 Park, L.B.S. Marg, Vikhroli West, Mumbai - 400083. Tel: 022 - 4918 6000 and Email:- rtt.helpdesk@in.mgms.mufg.com.

For Ajmera Realty & Infra India Limited
Sd/-
Manoj I. Ajmera
Managing Director

Date: July 25, 2025
Place: Mumbai

Balaxi Pharmaceuticals Limited

Registered Office: Plot No.409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598 | **Phone:** +91 40 23555300 | **Email:** secretarial@balaxi.in | **Website:** www.balaxipharma.in

INFORMATION REGARDING 82nd ANNUAL GENERAL MEETING TO BE HELD THROUGH VIDEO CONFERENCING ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM")

Notice is hereby given that the 82nd Annual General Meeting ("AGM") of the Members of Balaxi Pharmaceuticals Limited ("the Company") is scheduled to be held on Monday, August 25, 2025 at 11.00 a.m. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") in compliance with the applicable provisions of the Companies Act, 2013 ("the Act") and rules made thereunder read with General Circular no. 9/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs (MCA) and circular issued by Securities and Exchange Board of India (SEBI) vide circular no. SEBI/HO/CFD/CDDP-2/P/CIC/2024/133 dated October 03, 2024 ("SEBI Circular") and other applicable circulars and notifications issued (including any statutory modifications or re-enactments thereof for the time being in force and as amended from time to time). Companies are permitted to hold General Meetings through VCOAVM, without the physical presence of the members at a common venue.

In Compliance with the abovementioned circulars, Notice of the AGM along with the Annual Report 2024-25 will be sent only through electronic mode to those Members whose e-mail address is registered with the Company/ Registrar and Transfer Agent / Depository Participants / Depositories. Members may note that the Notice and Annual Report 2024-25 will also be available on the Company's website <https://balaxipharma.in/>, website of the Stock Exchange i.e., National Stock Exchange of India Limited <https://www.nseindia.com/>, and on the website of National Securities Depository Limited <https://www.evotingnsdl.com/>. The Company shall send physical copy of the Annual Report 2024-25 to the members who specifically request for the same by sending an email at secretarial@balaxi.in.

In compliance with Section 108 of the Act, read with the corresponding rules, Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of SEBI circulars, the Company is providing remote e-voting facility to its members, to enable them to cast their votes electronically through the facility provided by National Securities Depository Limited (NSDL). Additionally, the facility for voting during the AGM will also be made available. Members present in the AGM through VC/OAVM and who have not casted their vote on the resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through the e-voting system during the AGM. Detailed instructions for remote e-voting, e-voting during the AGM and attending the AGM through VC/ OAVM will be provided in the Notice of the AGM.

Members who have not registered their e-mail address are requested to register the same in respect of shares held in electronic form with the Depository through their Depository Participant(s) and in respect of shares held in physical form by writing to the Company's RTA, Aarthi Consultants Private Limited, 1-2-285, Domalguda, Hyderabad – 500 029. E-mail: info@aarthiconsultants.com.

Members holding shares in physical mode are requested to note that SEBI vide its circulars SEBI/HO/MIRSD/MIRSD-RTAMB/P/CIR/2021/655 dated November 3, 2021, SEBI/HO/MIRSD/MIRSD-RTAMB/P/CIR/2021/687 dated December 14, 2021 and SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 and SEBI/HO/MIRSD/PoD-1/P/CIR/2023/181 dated November 17, 2023 has simplified the process for investor service requests. SEBI has made it mandatory for holders of physical securities to furnish PAN, bank account details, contact details, specimen signature and nomination for their corresponding folio numbers. SEBI has notified forms for the purpose, as detailed below:

Forms	Description
Form ISR-1	Request for registering PAN, bank account details, signature, mobile, email-id, address or changes / up-dation thereof
Form ISR- 2	Confirmation of Signature of securities holder by the Banker
Form SH-13	Nomination form
Form ISR-3	Declaration for Nomination opt-out
Form SH- 14	Change in Nomination

The above forms can be downloaded from the Company's website at <https://balaxipharma.in/investor-centers>. Accordingly, members are requested to make service requests / update their records by submitting a duly filled and signed forms, along with the related proofs listed in the forms to Company's RTA, Aarthi Consultants Private Limited, 1-2-285, Domalguda, Hyderabad – 500 029. E-mail: info@aarthiconsultants.com.

For Balaxi Pharmaceuticals Limited

Sd/-
Mohith Kumar Khandelwal
(Company Secretary and Compliance Officer)
Membership No.: F11243

Date: July 24, 2025
Place: Hyderabad

